Cover Image
市場調查報告書

基因治療藥:儘管Glybera、 Strimvelis等產品面臨困難,開發平台的擴大及CAR-T細胞治療藥的認證反映商業性的魅力高漲

Gene Therapies: A Growing Pipeline and Approval of CAR-T Cell Therapies Reflect Increasing Commercial Appeal, Despite Difficulties Faced by products such as Glybera and Strimvelis

出版商 CBR Pharma Insights 商品編碼 604426
出版日期 內容資訊 英文 79 Pages
訂單完成後即時交付
價格
Back to Top
基因治療藥:儘管Glybera、 Strimvelis等產品面臨困難,開發平台的擴大及CAR-T細胞治療藥的認證反映商業性的魅力高漲 Gene Therapies: A Growing Pipeline and Approval of CAR-T Cell Therapies Reflect Increasing Commercial Appeal, Despite Difficulties Faced by products such as Glybera and Strimvelis
出版日期: 2018年01月01日 內容資訊: 英文 79 Pages
簡介

本報告提供基因治療藥調查分析,概要,主要產品,策略,課題,技術,及策略上檢討事項等系統性資訊。

第1章 目錄

第2章 基因治療藥概要

  • 基因治療藥的種類

第3章 現在已通過核準的基因治療藥

  • Glybera (alipogene tiparvovec)
  • Kynamro (mipomersen)
  • Macugen (pegaptanib)
  • Vitravene (fomivirsen)
  • Gendicine (rAd-p53)
  • Oncorine (rAd5-H101)
  • Neovasculgen (Pl-VEGF165)
  • Exondys 51 (eteplirsen)
  • Spinraza (nusinersen)
  • Strimvelis (GSK-2696273)
  • Kymriah (tisagenlecleucel)
  • Yescarta (axicabtagene ciloleucel)
  • Imlygic (talimogene laherparepvec)
  • Zalmoxis (Allogenic T cells encodng LNGFR and HSV-TK)
  • Luxturna (voretigene neparvovec)

第4章 基因治療藥的製造策略

  • 病毒媒介的製造
  • 細胞原來基因治療藥的製造

第5章 基因治療藥開發的課題

第6章 基因治療藥開發平台、新興技術

  • 基因治療藥開發平台:各治療領域、開發階段
  • 基因治療藥開發平台:各介入、媒介類型
  • CAR-T 細胞治療藥的開發平台
  • 企業定位
  • 初期的基因編輯技術

第7章 策略上檢討事項

  • 授權契約
  • 相互作用開發契約

第8章 結論

第9章 附錄

目錄
Product Code: GBI086CBR

Summary

GBI Research's latest report: "Gene Therapies: A Growing Pipeline and Approval of CAR-T Cell Therapies Reflect Increasing Commercial Appeal, Despite Difficulties Faced by products such as Glybera and Strimvelis" discusses all gene therapies, including not only those which involve genetic modification, but also RNAi, CAR-T cell and aptamer-based therapies.

In 2017 alone, the marketing approvals of Kymriah, Yescarta and Luxturna added to this growing class of products. However, due to various challenges, progress in developing this technology and achieving commercial uptake over the past few decades has been slow.

In the short term, there is a shortfall in global gene and cell therapy manufacturing capacity, and in the long-term the personalized nature of many gene and cell therapies represents a further challenge that will not be met by the currently used, centralized biopharmaceutical manufacturing model.

Additionally, the very small number of patients in orphan genetic diseases that these therapies are especially well suited for has caused commercial difficulties for drugs such as Glybera and Strimvelis, and the high pricing of these therapies in response to the low patient number presented strong reimbursement difficulties.

However, the pipeline for gene therapies is robust; there are 985 in vivo gene therapies, and a further 354 CAR-T cell therapies currently in pipeline development. Most are at an early stage of development, with 76% at the Discovery or Preclinical stage.

There are also currently 23 gene therapy programs in Phase III development. This CBR report provides a comprehensive view of the clinical, R&D, commercial and competitive landscape of Gene Therapy, and assesses key developments in delivery vector technology, and challenges and advances associated with the production of such vectors.

Scope

  • Why do gene therapies still occupy only a minimal market share in their respective indications?
  • What can be learned from the gene therapies that have already reached the market, especially from products that have faced commercial difficulties, such as Glybera and Strimvelis?
  • What are the prospects of recent approvals such as Luxturna, Kymriah and Strimvelis?
  • What are the relative advantages and disadvantages of each vector type and which hold the most promise?
  • What proportion of the overall gene therapy R&D pipeline is occupied by each vector type?
  • How will the entry of gene therapies into the market change the global manufacturing landscape?

Reasons to buy

  • Understand the current status of the field of therapeutic gene therapies, and the relative clinical and commercial success of currently marketed products.
  • Assess the pipeline for gene therapies split by therapy area, vector type and intervention type, and stage of development. Additionally, a granular assessment of the pipeline is provided across the four major therapy areas for gene therapy: oncology, central nervous system disorders, ophthalmology, and genetic disorders.
  • Gain a picture of the current competitive landscape, with a detailed breakdown of companies actively involved in the gene therapy pipeline.
  • Understand the level of involvement in the landscape on the part of big pharma companies, and the extent to how gene therapies fit into the overall portfolios of companies in this field.
  • Understand the strategic consolidations landscape in gene therapies across the past decade

Table of Contents

  • 1 Table of Contents
  • 1 Table of Contents 2
  • 1.1 List of Tables 3
  • 1.2 List of Figures 3
  • 2 Gene Therapy Overview 5
  • 2.1 Types of Gene Therapy 7
  • 2.1.1 Types of Intervention 8
  • 2.1.2 Types of Vector 13
  • 3 Currently Approved Gene Therapies 22
  • 3.1 Glybera (alipogene tiparvovec) 22
  • 3.2 Kynamro (mipomersen) 23
  • 3.3 Macugen (pegaptanib) 24
  • 3.4 Vitravene (fomivirsen) 25
  • 3.5 Gendicine (rAd-p53) 26
  • 3.6 Oncorine (rAd5-H101) 26
  • 3.7 Neovasculgen (Pl-VEGF165) 27
  • 3.8 Exondys 51 (eteplirsen) 28
  • 3.9 Spinraza (nusinersen) 29
  • 3.10 Strimvelis (GSK-2696273) 30
  • 3.11 Kymriah (tisagenlecleucel) 32
  • 3.12 Yescarta (axicabtagene ciloleucel) 33
  • 3.13 Imlygic (talimogene laherparepvec) 34
  • 3.14 Zalmoxis (Allogenic T cells encodng LNGFR and HSV-TK) 36
  • 3.15 Luxturna (voretigene neparvovec) 37
  • 4 Gene Therapy Production Strategies 38
  • 4.1 Production of Viral Vectors 38
  • 4.1.1 Case Study: Challenges in the Manufacture of AAV Vectors 40
  • 4.2 Production of Cell-based Gene Therapies 42
  • 5 Challenges to Gene Therapy Development 44
  • 6 Gene Therapy Pipeline and Emerging Technologies 46
  • 6.1 Gene Therapy Pipeline by Therapy Area and Stage of Development 46
  • 6.2 Gene Therapy Pipeline by Intervention and Vector Type 48
  • 6.3 Pipeline for CAR-T Cell Therapies 51
  • 6.4 Company Positioning 52
  • 6.4.1 Companies by Therapy Area 53
  • 6.4.2 Companies by Stage of Development 54
  • 6.4.3 Companies by Intervention Type 54
  • 6.4.4 Companies by Vector Type 56
  • 6.4.5 Companies Developing CAR-T Cell Therapies by Stage 57
  • 6.5 Early Genome Editing Technologies 57
  • 6.5.1 Zinc Finger Nucleases 58
  • 6.5.2 TALEN 58
  • 6.5.3 CRISPR-Cas9 59
  • 7 Strategic Consolidations 62
  • 7.1 Licensing Deals 62
  • 7.1.1 Licensing Deals by Region Value and Year 62
  • 7.1.2 Licensing Deals by Stage of Development and Value 64
  • 7.1.3 Licensing Deals by Intervention and Vector Type 65
  • 7.2 Co-development deals 66
  • 7.2.1 Co-development Deals by Region, Year and Value 66
  • 7.2.2 Co-development Deals by Stage of Development and Value 68
  • 7.2.3 Co-development Deals by Intervention and Vector Type 69
  • 8 Conclusion 71
  • 9 Appendix 72
  • 9.1 References 72
  • 9.2 About GBI Research 79

1.1 List of Tables

  • Table 1: Gene Therapies, Global, Methods of Gene Silencing, 2017 10
  • Table 2: Gene Therapies, Global, Types of Viral Vector for Gene Therapy Delivery, 2017 15
  • Table 3: Gene Therapies, Global, Types of Non-Viral Vector for Gene Therapy Delivery, 2017 19
  • Table 4: Gene Therapies, Global, Clinical Characteristics of Glybera, 2017 23
  • Table 5: Gene Therapies, Global, Clinical Characteristics of Kynamro, 2017 24
  • Table 6: Gene Therapies, Global, Clinical Characteristics of Macugen, 2017 25
  • Table 7: Gene Therapies, Global, Clinical Characteristics of Vitravene, 2017 25
  • Table 8: Gene Therapies, Global, Clinical Characteristics of Gendicine, 2017 26
  • Table 9: Gene Therapies, Global, Clinical Characteristics of Oncorine, 2017 27
  • Table 10: Gene Therapies, Global, Clinical Characteristics of Neovasculgen, 2017 27
  • Table 11: Gene Therapies, Global, Clinical Characteristics of Exondys 51, 2017 29
  • Table 12: Gene Therapies, Global, Clinical Characteristics of Spinraza, 2017 30
  • Table 13: Gene Therapies, Global, Clinical Characteristics of Strimvelis, 2017 32
  • Table 14: Gene Therapies, Global, Clinical Characteristics of Kymriah, 2017 33
  • Table 15: Gene Therapies, Global, Clinical Characteristics of Yescarta, 2017 34
  • Table 16: Gene Therapies, Global, Clinical Characteristics of Imlygic, 2017 35
  • Table 17: Gene Therapies, Global, Clinical Characteristics of Zalmoxis, 2017 36
  • Table 18: Gene Therapies, Global, Clinical Characteristics of Luxturna, 2017 37
  • Table 19: Gene Therapies, Global, Impurities in the AAV Production Process, 2017 41
  • Table 20: Gene Therapies, Global, Overall Challenges to Gene Therapy Development, 2017 44
  • Table 21: Gene Therapies, Global, Comparison of CRISPR-Cas9, ZFNs and TALENs as Gene Editing Platforms, 2017 57

1.2 List of Figures

  • Figure 1: Gene Therapies, Global, Definition of Gene Therapy, 2017 5
  • Figure 2: Gene Therapies, Global, Clinical Trials Approved for Gene Therapies, 1989-2012 6
  • Figure 3: Gene Therapies, Global, Timeline of Key Events in Gene Therapy Research, 1944-2017 7
  • Figure 4: Gene Therapies, Global, Types of Gene Therapy-based Intervention, 2017 8
  • Figure 5: Gene Therapies, Global, Types of Vector for Gene Therapy Delivery, 2017 14
  • Figure 6: Gene Therapies, Global, Specific Types of Vector for Gene Therapy Delivery, 2017 14
  • Figure 7: Gene Therapies, Global, Production of Viral Vectors for Gene Therapy; Genome Modification, 2017 39
  • Figure 8: Gene Therapies, Global, Viral Gene Therapy Vector Manufacture; General Production and Purification Scheme, 2017 40
  • Figure 9: Gene Therapies, Global, Gene Therapy Pipeline by Therapy Area and Stage of Development, 2017 46
  • Figure 10: Gene Therapies, Global, Gene Therapy Pipeline by Therapy Area and Stage of Development, 2017 47
  • Figure 11: Gene Therapies, Global, Gene Therapy Pipeline by Vector and Intervention Type, 2017 48
  • Figure 12: Gene Therapies, Global, Gene Therapy Pipeline by Vector and Therapy Area, 2017 49
  • Figure 13: Gene Therapies, Global, Gene Therapy Pipeline by Intervention Type and Therapy Area, 2017 50
  • Figure 14: Gene Therapies, Global, CAR-T Cell Therapies by Stage of development, 2017 51
  • Figure 15: Gene Therapies, Global, CAR-T Cell Therapies by Molecular Target, 2017 51
  • Figure 16: Gene Therapies, Global, Gene Therapy Pipeline Companies by Type and Level of Diversification, 2017 52
  • Figure 17: Gene Therapies, Global, Gene Therapy Pipeline by Company and Therapy Area, 2017 53
  • Figure 18: Gene Therapies, Global, Gene Therapy Pipeline by Company and Stage of Development, 2017 54
  • Figure 19: Gene Therapies, Global, Gene Therapy Pipeline by Company and Intervention Type, 2017 55
  • Figure 20: Gene Therapies, Global, Gene Therapy Pipeline by Company and Vector Type, 2017 56
  • Figure 21: Gene Therapies, Global, CAR-T Cell Therapy Pipeline by Company and Stage of development, 2017 57
  • Figure 22: Gene Therapies, Global, Licensing Deals by Year, 2006-2017 63
  • Figure 23: Gene Therapies, Global, Licensing Deals by Stage of Development and Value, 2006-2017 64
  • Figure 24: Gene Therapies, Global, Licensing Deals by Vector type, 2006-2017 65
  • Figure 25: Gene Therapies, Global, Licensing Deals by Intervention type, 2006-2017 66
  • Figure 26: Gene Therapies, Global, Co-Development Deals by Year, 2006-2017 67
  • Figure 27: Gene Therapies, Global,Co-Development Deals by Year and Value, 2006-2017 68
  • Figure 28: Gene Therapies, Global,Co-Development Deals by Vector, 2006-2017 69
  • Figure 29: Gene Therapies, Global,Co-Development Deals by Vector, 2006-2017 70
Back to Top